Subacute cutaneous lupus erythematosus in a patient of pancreatic cancer secondary to novel albumin-bound paclitaxel chemotherapy
Year: 2023
Type: article
Study design: Case Report
Abstract: Paclitaxel is commonly used for the treatment of breast, ovarian, gastrointestinal, and carcinoma of the head and neck. Paclitaxel treatment is often associated with hair loss, myalgia, acral erythema, scleroderma and Stevens–Johnson syndrome, peripheral neuropathy, nausea, vomiting, bone marrow suppression, and rarely cardiac electroconductive pathway abnormalities. However, its association with cutaneous/systemic lupus erythematosus has been sparsely described. In this case report, we are discussing a case of nab-paclitaxel-induced subacute cutaneous lupus erythematosus which has been described only once in the published literature.
Source: Indian Journal of Skin Allergy
Authors: Sumit Sehgal, Manish Jain, Srishti Agrawal, Chaitali Khedkar
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4387528504